# A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

> **NCT04432831** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1479 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Faricimab
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT04432831
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-05
- **Primary completion:** 2023-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 1479 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432831, "A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04432831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*